Price of ruxolitinib tablets/box of ruxolitinib in 2025

The original drug of Ruxolitinib Tablets/Ruxolitinib (Ruxolitinib) in the Chinese market is usually marketed as Ruxolitinib Phosphate Tablets and has been included in the reimbursement scope of Class B medical insurance. This means that eligible patients can enjoy partial medical insurance reimbursement when using ruxolitinib, thus reducing their financial burden. Common drug specifications are 20mg*14 tablets and 5mg*60 tablets.

According to market conditions, the price of ruxolitinib’s original drug is approximately around RMB 3,000 per box. The specific price will fluctuate according to different specifications and regions. The specification of 20mg*14 tablets is often used for higher dose treatment, while the specification of 5mg*60 tablets is suitable for long-term maintenance treatment. Prices are affected by various factors such as drug manufacturers, sales channels, and market demand, so prices may vary.

Overseas, the price of ruxolitinib also varies by region. For example, the price of a box of 5mg*60 tablets of the Turkish version of the original drug is approximately RMB 4,000. The price may fluctuate due to exchange rate fluctuations. It should be noted that although the overseas version of ruxolitinib is basically the same as the original drug in the Chinese market in terms of ingredients and effects, in terms of price, imported drugs are usually slightly more expensive than the domestic market price.

In addition to the original drug, generic versions of ruxolitinib have also been launched on the market. Taking the generic drugs produced by Lao pharmaceutical factories as an example, the price of each box of 5mg*60 tablets is about RMB 700. Generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, but they are more affordable and suitable for some patients with limited economic conditions.

Although the price of generic drugs is lower, since their production process and quality control may be different from the original drugs, patients with myelofibrosis should make decisions based on the advice of their doctors when choosing. On the premise of ensuring treatment efficacy and safety, choosing appropriate drugs can help reduce patients' financial pressure and improve their treatment experience.

Reference materials:https://www.jakavi.com/